Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review
Microorganisms · 19.07.2025 · 13 (7) · 1697
DOI: 10.3390/microorganisms13071697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 19.07.2025. Verfasst von Matthew E Falagas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, Marousi, 151 23 Athens, Greece. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Klebsiella pneumoniae carbapenemases (KPCs) are a group of class A β-lactamases of Gram-negative bacteria leading to difficult-to-treat infections. We evaluated the global epidemiology of KPC-producing Gram-negative clinical isolates. A systematic search of six databases (Cochrane Library, Embase, Google Scholar, PubMed, Scopus, and Web of Science) was conducted. Extracted data were tabulated and evaluated. After screening 1993 articles, 119 were included in the study. The included studies originated from Asia (n = 49), Europe (n = 29), North America (n = 14), South America (n = 11), and Africa (n = 3); 13 studies were multicontinental. The most commonly reported KPC-producing species were Klebsiella pneumoniae (96 studies) and Escherichia coli (52 studies), followed by Enterobacter cloacae (31), Citrobacter spp. (24), Klebsiella oxytoca (23), Serratia spp. (15), Enterobacter spp. (15), Acinetobacter baumannii complex (13), Providencia spp. (11), Morganella spp. (11), Klebsiella aerogenes (9), Pseudomonas aeruginosa (8), Raoultella spp. (8), Proteus spp. (8), and Enterobacter aerogenes (6). Among the studies with specific blaKPC gene detection, 52/57 (91%) reported the isolation of blaKPC-2 and 26/57 (46%) reported blaKPC-3. The antimicrobial resistance of the studied KPC-producing isolates was the lowest for ceftazidime–avibactam (0–4%). Resistance to polymyxins, tigecycline, and trimethoprim–sulfamethoxazole in the evaluated studies was 4–80%, 0–73%, and 5.6–100%, respectively. Conclusions: The findings presented in this work indicate that KPC-producing Gram-negative bacteria have spread globally across all continents. Implementing proper infection control measures, antimicrobial stewardship programs, and enhanced surveillance is crucial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, Marousi, 151 23 Athens, Greece.
- School of Medicine, European University Cyprus, 6 Diogenous Str., Egkomi, Nicosia 2404, Cyprus.
- Department of Medicine, Tufts University School of Medicine, Boston, 145 Harrison Ave, Boston, MA 02111, USA.
ORCID-Profile: Charalampos Filippou
Zitieren
APA
Falagas, M. E., Asimotou, C. M., Zidrou, M., Kontogiannis, D. S., & Filippou, C. (2025). Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review. Microorganisms, 13(7), 1697. https://doi.org/10.3390/microorganisms13071697
Vancouver
Falagas ME, Asimotou CM, Zidrou M, Kontogiannis DS, Filippou C. Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review. Microorganisms. 2025;13(7):1697. doi:10.3390/microorganisms13071697
BibTeX
@article{Falagas2025,
author = {Falagas, Matthew E and Asimotou, Christina-Maria and Zidrou, Maria and Kontogiannis, Dimitrios S and Filippou, Charalampos},
title = {Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {7},
pages = {1697},
doi = {10.3390/microorganisms13071697}
}
EUVIMED